Can Timolol Be Added to Vyzulta and Brinzolamide?
Yes, timolol can be added to your patient's current regimen of Vyzulta (latanoprostene bunod) and brinzolamide when intraocular pressure remains above target. This represents a rational escalation strategy supported by both guideline recommendations and clinical evidence.
Rationale for Adding Timolol
The 2021 Primary Open-Angle Glaucoma guidelines explicitly support this approach 1. Topical beta-adrenergic antagonists like timolol are commonly prescribed for glaucoma and have demonstrated good efficacy and tolerability 1. When target IOP is not achieved with initial therapy, adding medications from different drug classes is the recommended strategy 1.
Mechanism and Expected Benefit
Your patient is currently on:
- Vyzulta (prostaglandin analog + nitric oxide donor): increases trabecular and uveoscleral outflow
- Brinzolamide (carbonic anhydrase inhibitor): decreases aqueous production by 15-20% 1
Adding timolol (beta-blocker) would provide complementary IOP reduction through a third mechanism—further decreasing aqueous production 2. This multi-mechanistic approach is precisely what guidelines recommend when monotherapy or dual therapy fails to achieve target pressure 1.
Evidence Supporting This Combination
Multiple studies demonstrate the efficacy of adding timolol to prostaglandin analogs and carbonic anhydrase inhibitors:
Timolol added to prostaglandin + brinzolamide: A 2008 study showed that travoprost/timolol fixed combination plus brinzolamide reduced mean diurnal IOP to 17.3 mmHg compared to 22.3 mmHg with prostaglandin alone 3
Direct comparison studies: When added to prostaglandin analogs, both timolol and brinzolamide provide similar additional IOP reduction (approximately 4 mmHg), and combining all three is more effective than any two-drug combination 4, 5, 3
24-hour IOP control: Research shows that triple therapy with prostaglandin + carbonic anhydrase inhibitor + beta-blocker provides superior diurnal and nocturnal IOP control 6
Dosing and Administration
According to FDA labeling 2:
- Start with timolol 0.25% twice daily in the affected eye(s)
- If response is inadequate after 4 weeks, increase to timolol 0.5% twice daily
- The concomitant use of two topical beta-blockers is NOT recommended 2
Important timing consideration: Avoid nighttime dosing of beta-blockers, as this is associated with limited efficacy and may contribute to visual field progression via nocturnal reduction of systemic blood pressure 1.
Critical Safety Considerations
Contraindications and Precautions
Before adding timolol, screen for 1:
Absolute contraindications:
- Asthma or severe chronic obstructive pulmonary disease
- Sinus bradycardia, second or third-degree AV block
- Overt cardiac failure
- Cardiogenic shock
Relative contraindications requiring caution:
- Diabetes mellitus (may mask hypoglycemia symptoms)
- Myasthenia gravis
- Cerebrovascular insufficiency
- Depression
Monitor for systemic effects:
- Bradycardia (mean reduction 2.9 beats/minute) 2
- Decreased blood pressure
- Bronchospasm in susceptible patients
Common Pitfalls to Avoid
Don't use timolol at bedtime: This reduces efficacy and may worsen nocturnal hypotension 1
Don't combine with another beta-blocker: The FDA label explicitly warns against using two topical beta-blockers simultaneously 2
Don't skip the 4-week evaluation: IOP response to timolol requires several weeks to stabilize; evaluate after approximately 4 weeks 2
Consider cardioselective alternatives: If the patient has mild obstructive airway disease, betaxolol (beta-1 selective) may be safer, though it's less effective for IOP reduction 1
Alternative Considerations
If timolol is contraindicated or not tolerated, consider:
- Alpha-2 agonists (brimonidine): Though one study showed brimonidine provided less additional IOP reduction than timolol when added to prostaglandin analogs (2.3 mmHg vs 3.9 mmHg reduction) 4
- Rho kinase inhibitors (netarsudil): Provides 10-20% IOP reduction through increased trabecular outflow 1
Target Pressure Adjustment
Since your patient's IOP remains above target on dual therapy, reassess and potentially lower the target IOP 1. The guidelines recommend a target pressure at least 20% below baseline, but if pressure remains elevated or there's evidence of progression, a more aggressive target (25-30% reduction) may be necessary 1.
Monitor closely: Schedule follow-up in 2-4 weeks after adding timolol to assess IOP response and systemic side effects 7. If target IOP is still not achieved with triple therapy, consider laser trabeculoplasty or surgical intervention 1.